ZOMDF Zomedica Corp. Insider Trading

Sr VP Sales Kevin Klass buys 150,000 shares of ZOMDF at $0.10; stock up 149.4% in 90 days, insider's same-ticker buys well-timed at 90-day mark

Klass Russell Kevin, Sr Vice President of Sales, purchased 150,000 shares at $0.10 on 2025-11-13, expanding his holdings to 5,784,101 shares and representing a 2.7% increase. This marks the third consecutive buy in three days at Zomedica Corp., following purchases on 2025-11-10, 2025-11-07, and 2025-11-06. Over the prior 90 days, ZOMDF stock has appreciated 149.4%, and his two earlier same-ticker buys on 2025-08-12 each showed +142.8% 90-day returns, indicating a 100% timing accuracy rate at this ticker for measurable outcomes. However, the company remains unprofitable, with net income of $-6,121,000.00 against quarterly revenue of $8,095,000.00, and his rapid succession of accumulation over three consecutive trading days warrants observation of whether this reflects a specific catalyst or a sustained conviction play in a volatile microcap stock trading near its 52-week high of $0.11.

Sr VP Sales bought 120,000 shares of ZOMDF at $0.10 on 2025-11-10; 5th buy in 4 days; prior same-ticker buys showed +142.8% to +152.0% 90d returns.

Klass Russell Kevin, Sr Vice President Sales, purchased 120,000 shares at $0.10, expanding his holdings from 5,514,101 to 5,634,101 shares. This is his 5th purchase in 4 days at Zomedica (buys on 2025-11-07, 2025-11-06, and two on 2025-08-12 plus one on 2025-08-11). His prior same-ticker purchases show 90-day returns of +142.8% and +152.0%, with all 3 prior measurable outcomes exhibiting positive 90-day returns. The stock has moved +55.3% over the past 30 days and +143.9% over 90 days from substantially lower levels. He is currently buying into a stock trading 9.1% below its 52-week high of $0.11. The company is unprofitable (net income $-6.1M) with $8.1M quarterly revenue, though it posted +8.3% annual growth. This concentrated sequence of small purchases by a senior sales executive at a micro-cap biotech merits attention for the pattern of repetition and the historical accuracy of his prior same-ticker timing at this highly volatile stock.

SVP Sales Klass Russell Kevin buys 5,000 shares (ZOMDF) at $0.10; 3 of 3 prior buys at this ticker yielded 90-day gains of +142.8% to +152.0%

Klass Russell Kevin purchased 5,000 shares at $0.10 on 2025-11-07, bringing his holdings to 5,514,101 shares. This represents a continuation of repeated open-market purchases at Zomedica: he has executed 5 prior trades at this ticker, with 3 prior buys that have completed their 90-day measurement windows, each showing strong gains (buy on 2025-08-11: +152.0%, buy on 2025-08-12: +142.8% and +186.8%). The current price of $0.10 sits at -9.1% from the 52-week high, though it has advanced +47.1% over 30 days and +146.9% over 90 days. Notably, the company remains unprofitable (net income of $-6,121,000 in the latest quarter) despite modest annual revenue growth of +8.3%. The serial-purchase pattern at a distressed micro-cap with improving near-term momentum but persistent losses warrants close observation of whether the insider's timing track at this specific ticker (3 of 3 well-timed at 90 days) continues to hold.

Sr VP Russell Kevin bought 253,007 shares of ZOMDF at $0.08 on 2025-11-06, raising holdings to 5.51M shares (+4.8%).

Klass Russell Kevin, Sr Vice President of Sales, purchased 253,007 shares at $0.08 on 2025-11-06, representing a 4.8% increase in his stake to 5,509,101 shares. The stock has since moved +47.3% over 30 days and +167.4% over 90 days from the trade date, though it currently trades $0.02 below the 52-week high. Russell's prior trades at ZOMDF (5 total) showed exceptionally strong 30-day returns (+173.2% to +187.6% on the August trades), though those outcomes remain unmeasured beyond 30 days. His cross-ticker track record shows 13 prior buys with an average 90-day return of +10.4% but a 33.33% 90-day win rate, indicating inconsistent timing discipline overall. The company reported a $-6.1M net loss on $8.1M quarterly revenue, with an unprofitable full-year result, which contextualizes the highly volatile price action and suggests elevated execution risk in the underlying business.

Sr VP Sales Russell buys 1,056,064 shares (1.06M) at $0.04 in 3 transactions, raising stake +25.1%

Klass Russell Kevin, Sr Vice President of Sales, executed 3 separate open-market purchases totaling 1,056,064 shares at $0.04 between 2025-08-11 and 2025-08-12, investing $42,242.56 and increasing his holdings from 4,200,030 shares to 5,256,094 shares—a +25.1% increase in his position. The buys occurred at a price point $0.04 below the 52-week high of $0.08, though the stock is currently -50.0% from that high, suggesting a purchase during a depressed period relative to recent trading range. Russell's cross-ticker track record shows poor predictive value: his prior 9 open-market buys averaged just +0.2% over 30 days and -9.6% over 90 days with only a 20% win rate, though his same-ticker history at ZOMDF remains unresolved with outcomes not yet measurable. Zomedica itself is unprofitable (net income of $-7,398,000.00 over the most recent full fiscal year), though the company posted $6,964,000.00 in latest-quarter revenue and +8.3% annual revenue growth, leaving investors without clear fundamental justification for the purchase magnitude.

Sr VP of Sales buys 500,000 shares at $0.04 amid unprofitable fundamentals and -31.1% 90-day decline.

Klass Russell Kevin, Sr Vice President of Sales, purchased 500,000 shares at $0.04 on 2025-08-08, expanding his holdings by 15.6% to 3,700,030 shares. The timing occurs as the stock trades 50.0% below its 52-week high and down 31.1% over 90 days. Company fundamentals show revenue of $6,964,000.00 for the latest quarter against a net loss of $7,398,000.00, with the company unprofitable over its most recent full fiscal year despite 8.3% annual revenue growth. Across his open-market history at all tickers, this insider's prior 11 buys averaged a -9.6% 90-day return with a 20.00% win rate, indicating a track record of poorly timed accumulation decisions. The stock has since seen additional buys by this insider on 2025-08-11 and 2025-08-12 (5 subsequent trades within days of the initial purchase), but outcomes remain unmeasurable.

Zomedica Sr VP of Sales buys 500,000 shares (500.0K shares) at $0.04 in 2 transactions

Klass Russell Kevin, Sr Vice President of Sales at Zomedica Corp., executed 2 separate purchases totaling 500,000 shares for $19,500.00 at $0.04 on 2025-08-11, bringing his post-transaction holdings to 4,200,030 shares (+13.5% vs pre-transaction). The current stock price matches the transaction price at $0.04, though the stock is -50.0% from its 52-week high of $0.08. His cross-ticker track record shows 10 prior buys with an average 90-day return of -9.6% and a 20.00% win rate, while at ZOMDF specifically, prior trades remain unmeasurable or recent. The company reported revenue of $6,964,000.00 (latest quarter) against net income of $-7,398,000.00 and remains unprofitable on a full-year basis, with annual revenue growth of +8.3%. The insider's accumulation reflects a material position increase at depressed valuations relative to the 52-week range, though the weak profitability profile and lackluster cross-ticker timing history warrant scrutiny of the investment case.

COO Blair Anthony K purchases 100,000 shares (100.0K) at $0.05; holds 1,000,000 shares post-transaction amid cluster buy

Blair Anthony K (COO) executed 2 purchases totaling 100,000 shares for $4,963.75 at $0.05 per share on May 21, 2025, increasing holdings from 900,000 to 1,000,000 shares (+11.1%). This purchase occurs within a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated executive accumulation. The company carries significant challenges—net income of $-63,809,000.00 against quarterly revenue of $6,500,000.00—and trades -37.5% below its 52-week high despite 30-day price momentum of +4.6%. The COO's cross-ticker track record shows mixed outcomes (90-day average return -2.3%, win rate 33.33%), limiting confidence in this purchase as a directional signal. The clustering of multiple insider buys at depressed valuation warrants monitoring for underlying business developments or potential capital initiatives.

General Counsel Karen DeHaan-Fullerton buys 104,300 shares of ZOMDF at $0.05 in initial stake purchase.

DeHaan-Fullerton, serving as General Counsel and Corporate Secretary, purchased 104,300 shares at $0.05 for $5,006.40, establishing an initial position in Zomedica. The company operates at a significant scale with $6.5M in latest quarterly revenue but is deeply unprofitable, having recorded $-63.8M in net income over its most recent fiscal year. The transaction occurs at the lower end of the stock's 52-week range ($0.03–$0.08), approximately 37.5% below the 52-week high, though the stock has gained 3.1% over the past 30 days. This initial insider purchase by a senior executive in a financially distressed but revenue-growing biotech company merits monitoring, as insider accumulation patterns and broader operational turnaround execution will be critical signals going forward.

Director Johnny D Powers buys 500,000 shares of Zomedica at $0.05 for $23.0K, raising stake 17.1% to 3.42M shares

Director Johnny D Powers purchased 500,000 shares at $0.05, increasing his holdings by 17.1% to 3,425,000 shares. The stock currently trades at $0.05, unchanged from the transaction price, though it trades 37.5% below its 52-week high of $0.08. Fundamentally, Zomedica remains deeply unprofitable with a $-63.8M net loss in its most recent full fiscal year against $6.5M quarterly revenue. Notably, across Powers' cross-ticker open-market history, his prior 18 buys have generated an average 90-day return of -7.2% with only a 25.00% win rate, suggesting a mixed track record of capital allocation timing decisions.